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ABSTRACT 
Cancer cachexia is a muscle wasting condition that occurs in response to a malignant 
growth in the body. Cachexia is associated with heart failure and is estimated to be the immediate 
cause of death in about a third of all cancer patients. The purpose of this study was to investigate 
cardiac atrophy in the Apc
Min/+
 mouse model of colorectal cancer. Compared to age matched 
C57BL/6 (BL6) mice, Apc
Min/+
 body mass and heart mass were lower at 12 (11.1 ± 4.5% and 7.6 ± 
2.8%, respectively) and 20-weeks (26.1 ± 2.5% and 6.0 ± 3.8%, respectively) of age (P < 0.05). 
Immunoblot analysis revealed that these changes in mass were accompanied by increased 
activation of protein kinase B (Akt Thr 473: 74.4 ± 10.9% and 216.0 ± 19.6% ; Akt Ser 308: 161.6 
± 31.7% and 367.4 ± 41.6% at 12- and 20-weeks, respectively, (P < 0.05)), mammalian target of 
rapamycin (mTOR Ser2448: 23.2 ± 13.2% and 44.0 ± 16.4% at 12- and 20-weeks, respectively, (P 
< 0.05)), 5' adenosine monophosphate-activated protein kinase (AMPK: 19.6 ± 5.2% and 22.5 ± 
5.5% at 12- and 20-weeks, respectively, (P < 0.05)) and elevated levels of the autophagy regulator 
beclin1 (4.7 ± 3.3% and 9.5 ± 3.0% at 12- and 20-weeks, respectively, (P < 0.05)). No evidence of 
increased cardiac apoptosis, protein ubiquitination or activation of cardiac caspases or calpains was 
noted. Taken together, these data suggest that the cardiac atrophy that occurs in the 12- and 20-
week old Apc
Min/+
 mouse is relatively modest compared to that seen with other tumor models [1] 
and is associated with evidence of increased cardiac autophagy.  
 
Key words: Cancer cachexia; cardiac atrophy; Akt/mTOR; AMPK; autophagy 
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CHAPTER 1 
Introduction 
Cancer and heart diseases are the two leading causes of death in the United States. The 
total number of deaths worldwide due to cancer is estimated to have been greater than 7.5 million 
in 2008 alone. Deaths from cancer are projected to rise to over 11 million by the year 2030. 
Colorectal cancer is the third most common type of cancer and it is expected that this disease will 
claim the lives of almost 50,000 individuals in the United States during 2011.  
Cachexia is characterized by generalized muscle wasting accompanied by weakness and 
anorexia. According to the National Cancer Institute, this life threatening paraneoplastic syndrome 
is estimated to be the immediate cause of death in 20% to 40% of cancer patients [2]. The Apc
Min/+
 
mouse has a nonsense mutation at codon 850 in the Apc gene, resulting in a truncated protein 
product that predisposes these animals to both small and large intestine adenomas [3]. Given that 
these mice develop a condition analogous to colorectal cancer with subsequent progression into 
cachectic stage, this model has been widely used as a model for cancer cachexia related studies. 
People suffering from cancer are most likely to have multiple co-morbidities. These co- 
morbidities may include heart failure, pulmonary hypertension, and ischemic heart disease 
amongst others [4]. The presence of co-morbidity drastically affects the quality of life in cancer 
patients. With respect to cardiac disease, it is oftentimes difficult to ascertain the cause of heart 
failure in cancer patients as it is difficult to ascertain whether it may be due to a prevailing 
condition or if it is due to therapies related to the cancer treatment. Similarly, how cancer cachexia 
may affect the heart is not well understood.  
Cardiac remodeling is the alteration in shape, size or structure of the heart that occurs in 
response to increased stress [5]. Whether cardiac atrophy occurs during cancer progression in the 
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Apc
Min/+
 mice heart has, to our knowledge, has not been investigated. Similarly, the molecular 
mechanism(s) that may be responsible for such changes, if present, are currently unclear.  
 
Purpose 
The purpose of this study is to examine if cardiac atrophy occurs and the molecular 
mechanism(s) that may be responsible for atrophy, if present, during the progression of cancer 
cachexia in the Apc
Min/+
 mouse model of colorectal cancer. 
 
Specific Aims 
Colorectal cancer is the third leading cause of cancer deaths in the United States that is 
estimated to tax the American health care system over $14 billion a year [6]. The costs of this 
disorder in terms of human suffering are incalculable. Cachexia is oftentimes associated with 
advanced cancer and is considered to be responsible for close to a third of all cancer-related 
deaths. Recent data have suggested that cachexia causes atrophy of skeletal muscles through 
decreased protein synthesis and increases in protein degradation [7]. This decrease in protein 
synthesis is thought to occur, at least in part, through alterations in the activation of the 5' AMP-
activated protein kinase (AMPK), protein kinase B (Akt) and mammalian target of rapamycin 
(mTOR) signaling. Whether similar events occur in the heart has not been investigated. The 
primary objective of this study is to determine if cancer cachexia is associated with cardiac 
atrophy and whether this atrophy, if present, is characterized by alterations in AMPK and Akt/ 
mTOR pathway signaling. To accomplish this objective we will pursue the following specific 
aims:  
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Specific Aim 1: 
To determine if the total and phosphorylated levels of proteins in AMPK and Akt/mTOR pathways 
are altered in hearts of mice with cancer cachexia. 
 
Hypothesis: 
Total and phosphorylated levels of proteins in AMPK and Akt/mTOR pathways will be 
altered in the hearts of mice with cancer cachexia. 
 
Specific Aim 2: 
To observe if there is alteration in total protein degradation levels in hearts of mice with cancer 
cachexia. 
 
Hypothesis: 
There will be an increase in total protein degradation in hearts of mice with cancer 
cachexia compared to that observed in age matched control animals. 
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CHAPTER 2 
Review of Literature 
Introduction 
A review of the relevant literature concerning this study will be presented. The following 
areas of interest will be addressed: 1) Regulation of AMPK and Akt/mTOR pathway related 
proteins in cancer cachexia and 2) Interplay of apoptosis and autophagy in cancer cachexia. 
 
Regulation of AMPK and Akt/mTOR pathway related proteins in cancer cachexia   
The 5' adenosine monophosphate-activated protein kinase (AMPK) is an enzyme that is 
chiefly involved in cellular metabolism and energy balance in the body [8, 9]. The AMPK is a 
heterotrimer that is composed of three subunits (α, β and γ), each one of which plays a role in 
activation of the enzyme. The γ subunit of AMPK is responsible for detecting the changes in AMP 
: ATP ratio [10]. Any physiological or pathological condition that lowers ATP levels causes the γ 
subunit to bind to the β domain which results in a conformational change. This change in 
conformation in turn exposes the catalytic domain on α subunit which allows AMPK to be 
phosphorylated by upstream kinases.  
It is thought that the, AMPK is activated primarily due to a change in cellular energy levels 
although the mechanism of activation may differ depending upon the condition. During conditions 
of increased stress, a serine threonine kinase called LKB1 activates AMPK by phosphorylation at 
threonine 172 [11]. Like LKB1, transforming growth factor-β-activated kinase 1 (TAK1) can also 
phosphorylate AMPK and causes its activation. Although the exact mechanism of activation of 
AMPK by TAK1 remains unclear,  recent data suggest that AMPK is activated by LKB1 through 
tumor necrosis factor-related apoptosis inducing ligand (TRAIL) [12]. In addition to changes in 
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ATP levels, AMPK is also activated by via AMP independent mechanisms such as the Ca
2+
-
dependent upstream kinase CaMKKß [13] or by increased leptin levels [14].  
Recent studies have shown that AMPK is activated in the skeletal muscle of rats injected 
with Yoshida AH-130 ascites hepatoma cells or C26 adenocarcinoma cells. In addition to 
increased AMPK activation, these authors also noted that cachexia was associated with increased 
expression of muscle-specific ubiquitin ligases and elevations in ubiquitin mediated protein 
degradation [15]. Other studies have reported that AMPK activation causes protein degradation 
through autophagy [1]. Whether similar changes may occur in the cachectic has not been 
investigated.  
The mammalian target of rapamycin (mTOR) is a protein that functions as nutrient- 
sensing signaling molecule in mammalian cells and is involved in regulating cell survival and 
protein synthesis. mTOR is an upstream molecule for p70S6 kinase (p70S6k) and 4E-binding 
protein-1 (4EBP1) which are thought to be key regulators of protein synthesis. mTOR through 
its interaction with raptor and GβL together form the mTORC1 complex which controls the 
phosphorylation of p70s6k and the eukaryotic initiation factor-4E (EIF4E) binding protein. It is 
thought that the interaction between raptor and GβL / mTOR is dependent on availability of 
nutrients [16]. In low nutrient conditions, raptor is phosphorylated by AMPK which results in 
tight binding between raptor and mTOR [17] and an inhibition of protein translation.  
 p70s6k is a serine/threonine kinase which is involved in translation of mRNAs containing 
a terminal oligopolypyrimidine (TOP) track at their 5’ end, a process that is thought to be a rate- 
limiting step in protein synthesis [18]. The phosphorylation of p70s6k is dependent on its 
interaction with the mTOR-raptor complex although recent data has suggested that Pdk1 may 
also play a role via the activation of PI3K signaling. 4EBP1 is a downstream target of mTOR 
which is phosphorylated by mTORC1 complex under nutrient rich conditions [19]. 
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Phosphorylation of 4EBP1 causes release of EIF4E which allows the mRNA to interact fully with 
the ribosome. However in one study it is shown that inhibition of mTOR signaling by rapamycin 
causes an increase in EIF4E phosphorylation in human cancer cell line. It was shown that 
phosphorylation of EIF4E is independent of signal from mTORC1 complex and that the signal 
for its activation comes from the phosphatidylinositol-3 kinase (PI3K) and Mnk-mediated 
mechanisms [20].  
Several studies to date have shown that the mechanisms involved in activation of mTOR 
are blocked in cancer cachexia. Activation of mTOR by mTOR kinase is dependent on the 
interaction of raptor and GβL with mTOR. This mutual interaction is dependent on the 
availability of glucose and amino acids. In people with colorectal cancer the absorption of 
nutrients in small intestine is impaired and available nutrients may be directed towards the 
actively growing tumor cells which can deprive the body of essential nutrients and lead to 
muscle wasting. This condition can lead to AMPK activation and the phosphorylation of raptor. 
Phosphorylation of raptor causes tight interaction with mTOR and inhibits mTOR kinase 
activity. As a consequence mTOR goes into an inactive stage with the subsequent inhibition of 
protein synthesis. 
Akt is a serine/threonine protein kinase that is an upstream regulator of mTOR. Akt acts 
as a key molecule in several metabolic processes such as glucose metabolism, fatty acid 
metabolism and protein synthesis [21]. When phosphorylated, Akt activates mTOR which in 
turn phosphorylates EIF4E binding protein and p70s6k causing an increase in protein synthesis. 
In addition to the regulation of protein synthesis, Akt is also involved in cell survival functions 
by exerting its effect on anti-apoptotic molecules Bcl-2 and Foxo-1 [22, 23] and in the 
regulation of nitric oxide production by eNOS [24]. Recently it was shown that activation of 
Akt causes phosphorylation of Bad that is involved in anti-apoptosis [25]. 
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Although the role of Akt in cancer has been well documented, little is known about how it 
may be regulated during cancer cachexia. Recently Michelle and colleagues in 2010 proposed that 
Akt activation is down regulated in quadriceps and epididymal fat of male CD2F1 mice infected 
by colon-26 adenocarcinoma tumors. These researchers also showed that this down regulation of 
Akt is accompanied by an increase in expression of atrophy promoting genes Atrogin-1, MuRF-1, 
and Bnip3 [26].  Other work has suggested that the phosphorylation of Akt in the skeletal muscle 
of cancer cachectic patients is reduced by almost 55% when compared to levels seen in skeletal 
muscle obtained from normal patients. Surprisingly, this same group has also reported increases in 
Akt activation in liver of cachectic patients [27]. Similarly, work in rats with AH-130 hepatoma 
and in mice transplanted with C26 colon adenocarcinoma has demonstrated that the 
phosphorylation of Akt and its downstream effectors p70s6k and Gsk3β is increased in the skeletal 
muscles of cancer afflicted animals when compared to that observed in the non-tumor bearing 
animals. Whether Akt activation is present in the hearts of cachectic animals has, to our 
knowledge, not been investigated.  
 
Summary 
AMPK, Akt and the Akt effector molecules mTOR and p70s6k are intimately involved in 
the regulation of protein synthesis and cellular metabolism. The exact mechanism(s) regulating the 
activity of the molecules and their complex interplay in cancer cachexia remains unclear. 
Elucidating the differences between normal and cachectic tissue at the molecular level may be 
beneficial for dietary and pharmacological interventions designed for the treatment of heart failure 
in cancer cachexia. 
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Interplay of apoptosis and autophagy in cancer cachexia 
Apoptosis and autophagy are the two most common mechanisms that mediate cell death. 
The fate of cell survival depends on the signals that inhibit apoptotic and autophagy pathways. 
Autophagy is a catabolic process by which components of a cell are removed by a degradative 
process involving sequestration of parts of the cytoplasm in a double membrane vesicle to form an 
autophagosome [28]. During conditions of nutrient starvation autophagy is activated, which results 
in recycling up the macromolecular structures in autophagolysomes that can be reutilized again 
leading to cell survival [29]. The activation of autophagy pathway depends mainly on the state of 
mTOR and AMPK [30]. Rheb is a GTP binding protein that is involved in S6K signaling and in 
the activation of mTOR when amino acids are present. During the depletion of amino acids the 
Rheb is dissociated from mTOR and the activation of mTOR is prevented. During cachexia there 
is a greater depletion of available ATP in the body as a result of which the nutrient sensing 
molecule AMPKα is activated. Research by Matsui et al showed that autophagy is induced by 
glucose deprivation in cardiac myocytes by activation of AMPKα and inhibition of mTOR.  ULK1 
a mammalian homologue of the yeast autophagy regulator, Atg1 is a serine/threonine protein 
kinase which can promote or inhibit autophagy depending upon it phosphorylation status. Like 
Atg1, ULK1 is required for initiation of autophagy downstream of target of rapamycin. Under 
nutrient rich conditions mTOR phosphorylates ULK1 at S757 which results in the inhibition of 
autophagy. Conversely, the phosphorylation of ULK1 at S317 and S777 by AMPK promotes 
autophagy [31]. Whether cancer cachexia causes cardiac autophagy is not well understood.  
 Apoptosis or programmed cell death is a mechanism wherein cells die gradually in an 
orderly fashion. It is thought that apoptosis is regulated by members of Bcl2 family and the 
caspases [32]. Members of the Bcl2 family have both pro-apoptotic or anti-apoptotic functions 
[33]. Although Bcl-2 and Bcl-xL function as antiapoptotic factors, Bax and Bid are pro-apoptotic.  
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Apoptosis is regulated by both intrinsic and extrinsic signals [34]. The extrinsic pathway is 
activated when cytokines such as TNF-α bind to the receptors on cell surface [35]. The binding of 
TNF-α to its receptor results in the recruitment procaspase 8 to the cell membrane, which leads to 
the formation of a death inducing signaling complex. The activation of intrinsic apoptosis pathway 
is under the control of mitochondria and is regulated by increases in oxidative stress, cell 
starvation, or alterations in growth factors concentration [36]. During stressful conditions 
mitochondria initiate apoptosis by releasing cytochrome c which, in turn, causes the release of 
apoptotic protease- activating factor (Apaf-1) [37]. Apaf-1, in turn, causes the release of caspase 9 
which initiates the activation of other caspases and eventually cell death.  
The ubiquitin-proteasome pathway is the main non-lysosomal pathway for protein 
degradation in eukaryotes [38]. In this process, proteins are ubiquitinated by ubiquitin ligases 
which results in their being targeted for degradation by the 26S proteasome [39]. Ubiquitination is 
involved in controlling the cellular concentration of the tumor suppressor p53, Nf-kB and other 
cell cycle proteins that are known to be involved in the regulation of apoptosis [40]. How cachexia 
may affect the regulation of cardiac apoptosis has not yet been elucidated.  
 
Summary 
Although autophagy is a lysosomal mediated process of cell death, apoptosis is a process 
of programmed cell death mediated by mitochondrial release of cytochrome c or activation of 
death receptors. The role that either of these processes may play in cardiac atrophy during 
cachexia has yet to be investigated.  
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CHAPTER 3 
 
Cancer cachexia and cardiac atrophy in the Apc
Min/+
 mice model of colon cancer 
 
 
 
This chapter will be submitted for publication. 
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ABSTRACT 
Cancer cachexia is a muscle wasting condition that occurs in response to a malignant 
growth in the body. Cachexia is associated with heart failure and is estimated to be the immediate 
cause of death in about a third of all cancer patients.  The purpose of this study was to investigate 
cardiac atrophy in the Apc
Min/+
 mouse model of colorectal cancer.  Compared to age matched 
C57BL/6 (BL6) mice, Apc
Min/+
 body mass and heart mass were lower at 12 (11.1 ± 4.5% and 7.6 ± 
2.8%, respectively) and 20-weeks (26.1 ± 2.5% and 6.0 ± 3.8%, respectively) of age (P < 0.05). 
Immunoblot analysis revealed that these changes in mass were accompanied by increased 
activation of protein kinase B (Akt Thr 473: 74.4 ± 10.9% and 216.0 ± 19.6% ; Akt Ser 308: 161.6 
± 31.7% and 367.4 ± 41.6% at 12- and 20-weeks, respectively, (P < 0.05)), mammalian target of 
rapamycin (mTOR Ser2448: 23.2 ± 13.2% and 44.0 ± 16.4% at 12- and 20-weeks, respectively, (P 
< 0.05)), 5' adenosine monophosphate-activated protein kinase (AMPK: 19.6 ± 5.2% and 22.5 ± 
5.5% at 12- and 20-weeks, respectively, (P < 0.05)) and elevated levels of the autophagy regulator 
beclin1 (4.7 ± 3.3% and 9.5 ± 3.0% at 12- and 20-weeks, respectively, (P < 0.05)). No evidence of 
increased cardiac apoptosis, protein ubiquitination or activation of cardiac caspases or calpains was 
noted. Taken together, these data suggest that the cardiac atrophy that occurs in the 12- and 20-
week old Apc
Min/+
 mouse is relatively modest compared to that seen with other tumor models [1] 
and is associated with evidence of increased cardiac autophagy.  
 
Key words: Cancer cachexia; cardiac atrophy; Akt/mTOR; AMPK; autophagy 
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INTRODUCTION 
Cancer cachexia is a life endangering paraneoplastic syndrome characterized by loss of 
muscle mass and body weight that is accompanied by fatigue and generalized weakness [41]. 
According to National Cancer Institute, it is estimated that nearly one-third of deaths in cancer is 
due to cachexia [42]. The etiology of cachexia is multifactorial and is thought to be mediated, at 
least in part, by humoral factors that are secreted from or induced by the tumor which lead to an 
imbalance between the rates of protein synthesis and breakdown [43]. 
Colorectal cancer is the third leading cause of deaths due to cancer in United States and is 
characterized by neoplasms in the colon and rectum. Colorectal cancer originates from the 
epithelial cells and is most commonly due to a mutation in adenomatous polyposis coli (APC) 
gene [44]. The Apc
Min/+
 mouse is a well-recognized model for use in colorectal cancer studies that 
exhibits a nonsense mutation at codon 850 in the Apc gene [3]. This mutation results in a truncated 
protein that predisposes the mice to intestinal neoplasms. Similar to humans, the Apc
Min/+
 mouse 
exhibits intestinal neoplasms and severe muscle wasting with increasing tumor burden [45, 46].   
Work to date has largely focused on understanding the mechanisms of skeletal muscle loss 
in cancer cachexia. Burc and colleagues, (1968) first demonstrated that existence of cardiac 
atrophy in cancer patients when they noted that cancer patients had smaller hearts and exhibited a 
diminution of the QRS complex both findings consistent with changes in cardiac function. Later 
work by Tessitore et al., (1993) examining male Wistar rats that had been injected with Yosidha 
ascites hepatoma cells found that heart mass was decreased by 21% by day 4 and to 46% by day 
10 when compared to control animals [47]. The mechanism(s) responsible for the loss of cardiac 
mass in cancer cachexia have yet to be elucidated.  
 The objectives of this study were twofold: (i.) to determine if the Apc
Min/+
 mouse exhibits 
cardiac atrophy with cachexia and (ii.) to examine the molecular signaling mechanism(s) that may 
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be activated in the Apc
Min/+
 mouse heart during the cachectic response. We hypothesized that 
hearts from Apc
Min/+ 
mice would weigh less than their age matched control counterparts and that 
this decrease in cardiac mass would be associated with evidence of increased cardiac autophagy.  
 
MATERIALS AND METHODS  
Animals 
All procedures were performed as outlined in the Guide for the Care and Use of 
Laboratory Animals as approved by the Council of the American Physiological Society and the 
Animal Use Review Board of Marshall University and University of South Carolina. Young (12 
week, n=4) male C57BL/6 wild and Apc
Min 
mice and adult (20 week, n=4) male C57BL/6 and 
Apc
Min 
mice were purchased from Jackson Laboratories and maintained by Dr. James A. Carson 
(University of South Carolina). Animals were housed under a 12H: 12H dark-light cycle at 22° 
± 2 °C. Mice were provided standard rodent chow (Harlan Teklad Rodent Diet, no. 8604) and 
water ad libitum. After acclimatization the mice were sacrificed according to the regulatory 
guidelines of University of South Carolina and the samples were sent to Marshall University in 
dry ice for analysis. 
 
Materials 
Anti- Akt  (#9272),  mTOR  (#2972), p70s6k (#9202), S6 ribosomal protein (#2217), Nf-
kB p65 (# 3034), Stat-3 (#9132), AMPK-α (#2532),  Beclin1 (#3738), phosphorylated mTOR
 
Ser2448
 (#2971), phosphorylated Akt 
Thr308
(#9275), phosphorylated Akt 
Ser473
( #9271), 
phosphorylated p70s6k 
Thr421/Ser424 
(#9204),  phosphorylated S6 ribosomal protein
  Ser235/236
  (#4858), 
phosphorylated Nf-kB p65 
Ser536
,  phosphorylated Stat-3
 Tyr705
, phosphorylated AMPK-α Thr172 (#2535),  
Mouse IgG, and Rabbit IgG antibodies were purchased from Cell Signaling Technology (Beverly, 
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MA). HeLa Whole Cell Lysate (sc-2200) and L6 + IGF Lysate (sc-24727) were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA). Enhanced chemiluminescence (ECL) western blotting 
detection reagent was obtained from Amersham Biosciences (Piscataway, NJ).  Restore western 
blot stripping buffer was purchased from Pierce (Rockford, IL). All other chemicals were 
purchased from Sigma Aldrich (St. Louis, MO) or Fisher Scientific (Hanover, IL). 
 
Preparation of protein isolates and immunoblotting 
Hearts were pulverized in liquid nitrogen using a mortar and pestle until a fine powder was 
obtained. After washing with ice cold PBS, pellets were lysed on ice for 15 minutes in T-PER (2 
mL/1 g tissue weight) (Pierce, Rockford, IL) containing protease and phosphatase inhibitors and 
centrifuged for 10 minutes at 2000 X g to pellet particulate matter. This process was repeated 
twice and the supernatants used for protein concentration determination using the 660 nm assay 
(Pierce, Rockford, IL). Samples were diluted to a concentration of 2.5 μg/ μl in SDS loading 
buffer, boiled for 5 minutes at 95 °C, and 30 μg of protein were separated using 10% and 15% 
SDS-PAGE gels. Verification of transfer onto nitrocellulose membrane was determined by Ponceau 
staining and determination of equal loading between lanes and membranes was determined by 
using GAPDH as loading control. Protein detection was performed as outlined by the antibody 
manufacturer while immunoreactive bands were visualized with ECL (Amersham Biosciences). 
Exposure time was adjusted at all times to keep the integrated optical densities within a linear and 
non-saturated range, and band signal intensity was quantified by densitometry using a flatbed 
scanner (Epson Perfection 3200 Photo) and imaging software (AlphaEaseFC). Biotinylated ladder 
(Cell Signaling) was used as molecular mass standards and Hela Whole cell lysates along with L6 
+ IGF were included as positive controls. For direct comparisons between the concentration levels 
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of different signaling molecules, membranes were stripped and re-probed for different molecule 
with Restore western blot stripping buffer as detailed by the manufacturer (Pierce, Rockford, IL). 
 
Statistical analysis 
Results are presented as mean + SEM. Data were analyzed by using the Sigma Stat 3.0 
statistical program. Data were analyzed using a two-way ANOVA followed by the Student- 
Newman-Keuls post-hoc testing when appropriate. P <0.05 was considered to be statistically 
significant. 
 
RESULTS 
Cancer cachexia and heart weight 
Average body mass of the C57BL/6 mice was ~10% (25.8 ± 1.4 g vs. 23.2 ± 1.1 g; P< 
0.05) and ~26% (27.3 ± 0.7 g vs. 20.2 ± 0.8 g; P< 0.05) greater than their Apc
Min/+ 
counterparts 
at 12- and 20-weeks, respectively (Table 1). Compared to 12 week C57BL/6 mice, heart 
muscle mass was ~8% less (120.4 ± 3.9 mg vs. 111.2 ± 3.6 mg; P< 0.05) in the 12 week 
Apc
Min/+ 
mice.  Similarly, heart weights of 20-week old C57BL/6 mice were 6% greater than 
those of 20-week old Apc
Min/+ 
mice (115.8 ± 3.8 mg vs. 108.8 ± 5.9 mg; P< 0.05).  
 
Cancer cachexia in the Apc
Min/+
 mouse is associated with elevated cardiac Stat-3 and Nf-kB 
levels but not increased apoptosis. 
The amount of total and phosphorylated Nf-kB p65 were significantly higher in 12- (20.9 ± 
2.6%, 81.3 ± 3.7%) week and 20- (84.9 ± 10.6%, 171.2 ± 13.9%) week Apc
Min/+ 
mice (P< 0.05; 
Figure 1). Similarly, the amount of Stat-3 (28.1 ± 8.5%, 39.3 ± 10.6%) and phosphorylated Stat-3 
(74.8 ± 20.0% and 37.1 ± 12.4%) were higher in 12- and 20-week Apc
Min/+ 
mice (P< 0.05; Figure 
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2). No evidence of increased caspase-3 or caspase-9 activation or cardiac apoptosis with cancer 
was observed (data not shown). 
 
AMPKα phosphorylation is higher in the hearts of ApcMin/+ mice 
 Compared to that observed in the control animals the amount of total and phosphorylated 
AMPK were 4.5 ± 1.1%, 4.2 ± 2.6% and 19.6 ± 5.2%, 22.5 ± 5.5 % higher in the 12- and 20-week 
old Apc
Min/+
 mice, respectively (P< 0.05; Figure 3).  
 
Akt signaling is activated in the hearts of Apc
Min/+
 mice 
To investigate the cancer cachexic effects on the total and phosphorylated amounts of 
Akt, mTOR, p70s6k, EIF4E, S6rp we performed SDS-PAGE and western blot analysis using 
antibodies which recognize both the unphosphorylated and phosphorylated forms of these 
molecules. There were no differences in Akt protein content among different groups (Figure 4). 
Compared to C57BL/6 controls, the phosphorylation of Akt (Ser308) was ~1.5 and ~2.5 fold 
higher in the 12- and 20-week Apc
Min/+
 mice, respectively (P< 0.05; Figure 4). Similarly, with 
cancer the amount of phosphorylated Akt (Thr473) was ~ 0.75 and ~1.25 fold higher in 12- and 
20-week Apc
Min/+
 mice, respectively (P< 0.05; Figure 4). The expression of mTOR was 
significantly higher in 12 week and 20 week Apc
Min/+ 
mice by 38.5 ± 8.1% and 17.1 ± 7.6% 
compared to age matched C57BL/6 mice controls (P< 0.05; Figure 5). The total level of p70s6k 
was 23.2 ± 2.4% lower in 12 week Apc
Min/+
 mice and 19.3 ± 3.5%   higher in 20 week Apc
Min/+
 
mice compared to that observed in age-matched control animals (P< 0.05; Figure 6). Immunoblot 
analysis using phospho-specific antibodies indicated that the total phosphorylation level of 
mTOR (Ser2448) and p70s6k (Thr421/Ser424) were 23.2 ± 13.2%, 44.0 ± 16.4% and 36.5 ± 
9.4%, 104.9 ± 24.8% higher, respectively in 12- week and 20-week Apc
Min/+
 mice compared to 
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age-matched controls (P< 0.05; Figures 5, 6).  The levels of S6rp were decreased in both 
cachexic groups compared to their controls while the phosphorylation of S6rp was decreased in 
20- week Apc
Min/+
 mice (P< 0.05; Figure 7). Phosphorylated levels of Bad at Ser136 were 
significantly increased in both 12 week and 20 week Apc
Min/+ 
mice by approximately 100% and 
74%, respectively (P< 0.05; Figure 8).   
 
Expression of autophagy regulating proteins but not calpain expression or protein 
ubiquitination is increased in cancer-induced cachexic hearts  
 It is thought that muscle utilizes three different proteolytic pathways to regulate muscle 
protein breakdown: calcium-dependent calpains, the ubiquitin-proteasome system and autophagy 
[1]. Compared to that observed in the control animals, no evidence of calpain activation (data not 
shown) or increased ubiquitination was observed in the Apc
Min/+
 mice (data not shown). 
Conversely, immunoblot analysis revealed that the expression of the autophagy regulator Beclin1 
was 4.7 ± 3.3% and 9.5 ± 3.0% higher in the 12- and 20-week old Apc
Min/+
 mice, respectively (P< 
0.05; Figure 9).   
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DISCUSSION 
Cancer cachexia is thought to be the cause of about 30% of all cancer-related deaths. 
How cancer may affect cardiac mass is only just now beginning to be investigated. Although 
cardiac mass in the Apc
Min/+
mouse colorectal cancer model was decreased at both 12- and 20-
weeks when compared to age-matched control animals there was not a significant decrease in 
the heart to body weight ratio in 12-weeks Apc
Min/+
mouse (Table 1). These data suggest that 
cardiac atrophy does not occur to a significant extent in the Apc
Min/+
 mouse. This finding is 
interesting given that the degree of gastrocnemius (-41%) and soleus (-26%) muscle atrophy in 
the 20-week old Apc
Min/+
 mouse is quite apparent [48]. Taken together, these data are consistent 
with the possibility that different muscle types exhibit different susceptibility to atrophy. This 
finding is not new. It is well established that the slow twitch soleus muscle is more sensitive to 
unloading-induced atrophy than the fast twitch plantaris muscle [49]. Why different muscle 
types might experience different degrees of muscle loss following exposure to atrophic stimuli 
is not well understood.  
It appears that the effects of colorectal cancer on cardiac mass may be different from 
that observed in other cancer models. For example, using the Yoshida tumor implant model 
Costelli and Melloni demonstrated significant loss of cardiac mass within six to ten days of 
implant [50]. More recently, Cosper and Leinwand using colon-26 adenocarcinoma implants 
showed that cardiac mass was decreased by approximately 8% and 21 % at 15 and 27 days post 
implantation, respectively [1]. The reason(s) why different cancer models may affect the 
regulation of heart mass differently is not clear but could be related to the amount or type of 
humoral factors released by the tumor. For example, the muscle wasting seen in the Yoshida 
heptatoma ascites model is generally considered to be the result of elevations in TNF-alpha 
 19 
 
while muscle loss in the colon-26 adenocarcinoma tumor implant model has been shown to be 
associated with increases in the amount of IL-1, IL-6, IL-12 and TNF-alpha [51-53].  
In the case of the Apc
Min/+
 mouse model, it is generally thought that the atrophy induced 
in this model is due to an elevation in serum IL-6 levels [41, 46, 48]. How IL-6 may affect 
cardiac structure or function is poorly understood. Recent data suggests that burn injury and 
sepsis are associated with cardiac inflammation, increased apoptosis and depressed contractile 
function [54, 55]. Similar to the Apc
Min/+
 mouse model, these aforementioned conditions are 
characterized by sustained increases in IL-6 levels. Other work has demonstrated that IL-6 can 
activate AMPK [56]. In the present study we found evidence of increased NF-kB and Stat-3 
activation which are consistent with the possibility of increased cardiac inflammation (Figures 
1, 2). In addition, we also found increases in pAMPK levels (Figure 3). Whether the increases 
in pAMPK we observe are due to elevations in IL-6, changes in nutrient uptake secondary to 
colon tumor load, or some combination of the two is currently unclear.  
In contrast to that observed in the septic and burn models we did not find any evidence 
of increased cardiac apoptosis (data not shown). This finding is similar to what others have seen 
upon investigating cardiac atrophy in the C-26 adenocarcinoma tumor implant model (Cosper 
and Leinwand). Given that elevations in IL-6 levels can cause cardiac apoptosis, our findings, 
along with those of Cosper and Leinwand, were quite surprising initially. To try to ascertain the 
potential mechanism(s) behind this finding we examined the phosphorylation status of Akt. The 
Akt is a serine / threonine kinase which is involved in the regulation of cell metabolism and cell 
death [57]. With cancer, we found an elevation in Akt phosphorylation at both Thr 308 and Ser 
473 (Figure 4) which is consistent with Akt activation. Given that Akt activation is strongly 
anti-apoptotic, we interpret these data to suggest that this is a compensatory response that is 
initiated to stave off the possibility of IL-6 induced cardiomyocyte apoptosis. In addition to 
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Akt, the activation of mTOR has also been shown to inhibit cellular death [58]. Similar to our 
findings for Akt, we also found significant elevations in mTOR phosphorylation with cancer. 
To confirm these findings, we next examined the phosphorylation of p70S6k which is a 
downstream substrate of mTOR. As expected, we found elevations in the activation 
(phosphorylation) of p70S6k and its downstream effector Bad (Figures 4, 8). Like Akt, Bad is 
intimately involved in regulating the transition between cellular life and death. In its 
unphosphorylated form Bad is strongly apoptotic [59, 60]. Conversely, when phosphorylated, 
the apoptotic activity of Bad is inhibited and cell death is prohibited. We suspect that the 
elevations in the phosphorylation of Akt, mTOR, p70S6k and Bad that we observe in the APC 
min mouse are an attempt by the cardiomyocyte to minimize cardiac apoptosis and preserve 
cardiac function. In an effort to further investigate this possibility we next examined the 
phosphorylation of the downstream effector of p70s6k, S6rp.  In 20 weeks Apc
Min/+ 
mice we 
found activation of Akt and mTOR and p70s6k (Thr421/Ser424), but a decrease in activated 
S6rp (Figure 7). These data suggest that the p70S6k activation we observe is most likely 
directed towards anti-apoptotic signaling and not for the purpose of increasing protein 
synthesis.  
It is thought that muscle utilizes three different proteolytic pathways to regulate muscle 
protein breakdown: Ca-dependent calpains, the ubiquitin-proteasome system and autophagy [1]. 
Autophagy is a mechanism for cell protection in which intracellular substances are degraded 
and the subsequent products recycled again. The breakdown of proteins that are not used in 
cellular metabolism leads to production of amino acids. On the basis of recent data suggesting 
that cancer cachexia is associated with increased autophagy [1] and other findings 
demonstrating that increased AMPK phosphorylation can stimulate this process [61] we next 
examined the regulation of beclin1. Our data demonstrated that cancer was associated with 
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beclin1 levels (Figure 9). These data suggest that changes in cardiac mass in the Apc
Min/+ 
mouse 
may be associated with autophagy.  
Taken together, our data suggest that cachexia in the Apc
Min/+ 
mouse model is associated 
with inflammation but not cardiac atrophy. Given the absence of changes in cardiac mass, cardiac 
apoptosis and protein ubiquitination we suspect that the activation of Akt, mTOR and p70s6k 
observed in the present study are more related to efforts directed at maintaining cell survival rather 
than increasing protein synthesis (Figure 10). Future studies designed to directly test this 
possibility will no doubt be useful in better understanding the effects of colorectal cancer on the 
heart.  
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                                                         APPENDIX 
 
TABLES AND FIGURES 
 
TABLE 1 
Animals Heart Weight (mg) Body Weight (gm) Hrt. / B.W. Ratio 
12 week BL6 mice 120.4 ± 3.9 25.7 ± 1.4 4.7 ± 0.12 
12 week Apc
Min/+ 
mice 111.2 ± 3.6* 23.1 ± 1.1* 4.8 ± 0.3 
20 week BL6 mice 115.8 ± 3.8 27.3 ± 0.3 4.2 ± 0.2 
20 week Apc
Min/+ 
mice 108.8 ± 5.9* 20.1 ± 0.8* 5.4 ± 0.5* 
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FIGURE LEGENDS 
Figure 1. Total and phosphorylated levels of Nf-kB p65 is altered in colorectal cancer 
induced cachexia. Total and phosphorylated levels of Nf-kB p65 in BL6 and Apc
Min/+ 
mice at 12- 
and 20-weeks. Results are expressed as arbitrary units for comparison. An asterisk (*) indicates 
significant differences in Apc
Min/+
 mice from the BL6 age matched controls (P< 0.05). 
 
Figure 2. Total and phosphorylated levels of Stat-3 are altered in colorectal cancer induced 
cachexia. Total and phosphorylated levels of Stat-3 at Tyr 705 in BL6 and Apc
Min/+ 
mice at 12- 
and 20-weeks. Results are expressed as arbitrary units for comparison. An asterisk (*) indicates 
significant differences in Apc
Min/+
 mice from the BL6 age matched controls (P< 0.05). 
 
Figure 3. Total and phosphorylated levels of AMPKα are altered in colorectal cancer 
induced cachexia. Total and phosphorylated levels of AMPKα at Thr172 in BL6 and ApcMin/+ 
mice at 12- and 20-weeks. Results are expressed as arbitrary units for comparison. An asterisk (*) 
indicates significant differences in Apc
Min/+
 mice from the BL6 age matched controls (P< 0.05). 
 
Figure 4.  Cancer cachexia is associated with activation of cardiac Akt.  Heart muscles from 
BL6 and Apc
Min/+
 were analyzed by Western blot analysis for cachexia-related changes in total and 
phosphorylated levels of Akt at Ser 308 and Thr473. Results are expressed as arbitrary units for 
comparison. An asterisk (*) indicates significant differences in Apc
Min/+
 mice from the BL6 age 
matched controls (P< 0.05). 
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Figure 5. Cancer cachexia induced changes in total and phosphorylated levels of mTOR. 
Total and phosphorylated levels of mTOR at Ser2448 were analyzed by immunoblotting. Results 
are expressed as arbitrary units for comparison. An asterisk (*) indicates significant differences in 
Apc
Min/+
 mice from the BL6 age matched controls (P< 0.05). 
 
Figure 6. Total and phosphorylated levels of p70s6k are altered in cancer cachexia. 
Immunoblot analysis for total and phosphorylated p70s6k at Thr421/Ser424 in BL6 and Apc
Min/+ 
mice of 12 and 20 weeks. Results are expressed as arbitrary units for comparison. An asterisk (*) 
indicates significant differences in Apc
Min/+
 mice from the BL6 age matched controls (P< 0.05). 
 
Figure 7. Total and phosphorylated levels of S6 ribosomal protein is altered in cancer 
cachexia. Total and phosphorylated levels of S6RP at Ser235/236 in BL6 and Apc
Min/+ 
mice at 12- 
and 20-weeks. Results are expressed as arbitrary units for comparison. An asterisk (*) indicates 
significant differences in Apc
Min/+
 mice from the BL6 age matched controls (P< 0.05). 
 
Figure 8. Phosphorylated levels of Bad are altered with cancer induced cachexia. 
Phosphorylated levels of Bad at Ser136 in BL6 and Apc
Min/+ 
mice at 12- and 20-weeks. Results are 
expressed as arbitrary units for comparison. An asterisk (*) indicates significant differences in 
Apc
Min/+
 mice from the BL6 age matched controls (P< 0.05). 
 
Figure 9. Alterations in autophagy indicator molecule Beclin1 is associated with cancer  
cachexia. Total levels of Beclin1 in BL6 and Apc
Min/+ 
mice at 12- and 20-weeks of age. Results are 
expressed as arbitrary units for comparison. An asterisk (*) indicates significant differences in 
Apc
Min/+
 mice from the BL6 age matched controls (P< 0.05). 
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Figure 10.  Schematic representation of different pathways involved in cancer induced 
cardiac cachexia in Apc
Min/+
 mice. 
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CHAPTER 4 
Conclusions 
1. The amount of total and phosphorylated AMPK, and Akt/mTOR are altered in hearts of 
Apc
Min/+ 
mice. 
2. There is no change in overall ubiquitination in ApcMin/+ compared to age matched BL6 
controls. However there is an increase in autophagy in Apc
Min/+ 
as indicated by 
expression of beclin1. 
3. Total and phosphorylated levels of proteins in Nf-kB and Stat-3 are increased in hearts 
of mice with cancer cachexia. 
4. The degree of cardiac atrophy seen in the ApcMin/+ mouse cancer model is less than that 
observed in other rapidly growing tumor models. Given the interaction between different 
signaling pathways, we suspect that cardiac mass is maintained by increased Akt/mTOR 
pathway signaling which acts to counterbalance the increases in AMPK and beclin1 
activation. 
 
Future Directions 
 Future directions based on this study should be aimed at the effects of cancer cachexia on 
cardiac function and its structure. How cancer cachexia effects cardiac function remains unclear 
and needs to be investigated in order to go for therapeutic intervention. Previous studies have 
shown that mice injected with colon-26 adenocarcinoma exhibited a significantly reduced 
fractional shortening compared to their controls. The same researchers found that mRNA and 
protein levels for MHC were altered with a decrease in MHCalpha (adult isoform) and an increase 
in MHCbeta (fetal isoform) indicating reactivation of the fetal gene expression [62]. A similar 
study conducted by a different group showed that left ventricular systolic diameter was increased 
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and diastolic posterior wall thickness was decreased significantly in tumor-bearing mice indicating 
a severe cardiac dysfunction [63]. However it is interesting to find out if similar changes would be 
seen in Apc
Min/+ mice model of colon cancer.  
 It is also worthwhile to see if the changes associated with cardiac dysfunction correlate 
with altered cardiac structure and any evidence of marked fibrosis. Tian.M (2010) showed that 
mice injected with colon-26 adenocarcinoma exhibited increased fibrosis and transmission 
electron microscopy revealed disrupted myocardial ultrastructure [62]. A more recent study 
conducted on both male and female mice bearing tumors showed that there is a marked increase in 
fibrosis by 50% and 65% compared to their controls along with myocellular disarray. The same 
group also showed that cardiac atrophy in this case was associated with a decrease in myocyte size 
but not an increase in cell death [1]. It is however unknown if similar changes exist in Apc
Min/+ 
mice with colon cancer. 
Cardiac muscle exhibits two isoforms of myosin (alpha and beta). While alpha is the 
predominant form in the healthy heart, a switch to the beta form occurs in a failing heart. The 
significant difference between the two isoforms is that alpha isoform can contract quickly utilizing 
more ATP while the beta isoform contracts slowly and strongly utilizing lesser ATP. It is thought 
that the increased workload or decreased activity of the glycolytic pathway might induce the 
change in isoform expression in order to maintain its normal function.[64, 65]. Previous work has 
demonstrated that diabetes, cardiomyopathy and exposure to hypoxia result in changes in cardiac 
myosin heavy chain expression [66-68] . Recent studies have reported a change in isoform switch 
in cachexic models which are injected with either with C-26 adenocarcinoma or Yoshida AH-130 
ascites hepatoma cells [1]. Whether a similar finding may exist in the Apc
Min/+ 
mouse has, to our 
knowledge, not been investigated. 
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